ClinicalTrials.gg
CompletedNCT00289796Updated Feb 8, 2017

Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine

A Phase 2 interventional study of DTPa-HBV-IPV/Hib in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 1 site in Germany. Open to participants aged 2 Days to 5 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
2 Days to 5 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Hepatitis B.

Enrollment
15th of 16
121 · median 417
Started
2004
the only one that year
Phase 2
3 of 16
none open now
Registered
1st of 16
by date
Lead sponsor
14 of 16
GlaxoSmithKline

Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, this one is the 15th largest by enrollment, is the only one that started in 2004, is one of 3 in phase 2, and was the 1st registered.

Hepatitis B

1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

None of the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 2 Days to 5 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B as a file.
02

Study summary

This study will assess immunogenicity, safety and reactogenicity of primary and booster vaccination.

Read the detailed description

"There will be two groups in this study:

  • one group will receive a birth dose of Pa vaccine and 3 doses of DTPa-HBV-IPV/Hib vaccine as primary vaccination and a dose of DTPa-HBV-IPV/Hib vaccine as booster vaccination
  • the control group will receive a birth dose of hepatitis B vaccine and 3 doses of DTPa-HBV-IPV/Hib vaccine as primary vaccination and a dose of DTPa-HBV-IPV/Hib vaccine as booster vaccination".
03

Conditions studied

  • Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
2 Days to 5 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria For the primary vaccination phase

  • Healthy newborn male or female infant 2 to 5 days old at the time of the first vaccination \& written taken from the parents/guardians of the subject
  • Born at term (gestational age 37-42 weeks) after an uncomplicated pregnancy
  • Birth weight >= 2.5 kg and 5 minute Apgar >= 7
  • Mother seronegative for surface antigen (HBsAg) For the booster vaccination phase
  • A healthy male or female between, and including, 12 and 23 months of age at the time of booster vaccination who has completed the primary vaccination course in the primary vaccination phase with written informed consent obtained from the parent or guardian of the subject

Exclusion criteria For the primary vaccination phase

  • Mother known or suspected to be seropositive for (testing not required for inclusion)
  • Planned use of any or non-registered product (drug or vaccine) other than the study vaccines during the study
  • Planned administration of immuno-suppressants or other immune-modifying drugs, administration of immunoglobulins and/or any blood products since birth or planned administration during the study.
  • Administration of immunoglobulins and/or any blood products to the mother during pregnancy
  • Neonatal jaundice requiring parenteral treatment (light therapy for physiological jaundice is allowed)
  • At risk of pneumococcal disease or planning to receive Prevenar™ during the study period
  • Administration or planned administration of BCG vaccination during the study period
  • Acute disease at the time of vaccination. For the booster vaccination phase
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose, or planned use during the booster phase.
  • Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination since the study conclusion visit of the primary vaccination phase.
  • Any confirmed or suspected or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  • Administration/ planned administration of a vaccine not foreseen by the study protocol, administration/ planned administration of immunoglobulins and/or any blood products during the period starting 30 days before the administration of the booster dose and ending 30 days after the booster dose.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose."
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    Infanrix hexa Group

    Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.

    Biological: DTPa-HBV-IPV/Hib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of seropositive subjects for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    A seropositive subject was defined a subject with antibody concentrations ≥ 5 EL.U/mL.

    Time frame: At Month 0

  2. Number of seropositive subjects for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    A seropositive subject was defined a subject with antibody concentrations ≥ 5 EL.U/mL.

    Time frame: At Month 3

  3. Number of seropositive subjects for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    A seropositive subject was defined a subject with antibody concentrations ≥ 5 EL.U/mL.

    Time frame: At Month 5

  4. Number of seropositive subjects for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    A seropositive subject was defined a subject with antibody concentrations ≥ 5 EL.U/mL.

    Time frame: At Month 7

  5. Antibody concentrations for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

    Time frame: At Month 0

  6. Antibody concentrations for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

    Time frame: At Month 3

  7. Antibody concentrations for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

    Time frame: At Month 5

  8. Antibody concentrations for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

    Time frame: At Month 7

  9. Number of seropositive subjects for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    A seropositive subject was defined a subject with antibody concentrations ≥ 5 EL.U/mL.

    Time frame: At Month 1 Post-Booster

  10. Antibody concentrations for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

    Time frame: At Month 1 Post-Booster

  11. Modified vaccine response for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Modified vaccine response was defined as: For initially seronegative subjects, antibody concentration 5 EL.U/mL at one month after the third dose of Infanrix hexa™. For initially seropositive subjects: antibody concentration at one month post vaccination 0.25 fold the pre-vaccination antibody concentration.

    Time frame: At Month 7

  12. Modified vaccine response for anti-pertussis toxoids (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Modified vaccine response was defined as: For initially seronegative subjects, antibody concentration 5 EL.U/mL at one month after the third dose of Infanrix hexa™. For initially seropositive subjects: antibody concentration at one month post vaccination 0.25 fold the pre-vaccination antibody concentration.

    Time frame: At Month 1 Post-Booster

  13. Number of seroprotected subjects for anti-Hepatitis B surface antigen (anti-HBs) antibodies

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.

    Time frame: At Month 7

  14. Number of seroprotected subjects for anti-Hepatitis B surface antigen (anti-HBs) antibodies

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.

    Time frame: At pre-booster vaccination (Month 0 BST)

  15. Number of seroprotected subjects for anti-Hepatitis B surface antigen (anti-HBs) antibodies

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.

    Time frame: At Month 1 post-booster vaccination

  16. Antibody concentrations for anti-Hepatitis B surface antigen (anti-HBs) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 10 mIU/mL.

    Time frame: At Month 7

  17. Antibody concentrations for anti-Hepatitis B surface antigen (anti-HBs) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 10 mIU/mL.

    Time frame: At pre-booster vaccination (Month 0 BST)

  18. Antibody concentrations for anti-Hepatitis B surface antigen (anti-HBs) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 10 mIU/mL.

    Time frame: At Month 1 post-booster vaccination

  19. Number of seroprotected subjects for anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At Month 7

  20. Number of seroprotected subjects for anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At pre-booster vaccination (Month 0 BST)

  21. Number of seroprotected subjects for anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At Month 1 post-booster vaccination

  22. Antibody concentrations for anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.1 IU/mL.

    Time frame: At Month 7

  23. Antibody concentrations for anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.1 IU/mL.

    Time frame: At pre-booster vaccination (Month 0 BST)

  24. Antibody concentrations for anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibodies

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.1 IU/mL.

    Time frame: At Month 1 post-booster vaccination

  25. Number of seroprotected subjects for anti-polyribosyl ribitol phosphate (anti-PRP)

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.15 g/mL.

    Time frame: At Month 7

  26. Number of seroprotected subjects for anti-polyribosyl ribitol phosphate (anti-PRP)

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.15 g/mL.

    Time frame: At pre-booster vaccination (Month 0 BST)

  27. Number of seroprotected subjects for anti-polyribosyl ribitol phosphate (anti-PRP)

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.15 g/mL.

    Time frame: At Month 1 post-booster vaccination

  28. Antibody concentrations for anti-polyribosyl ribitol phosphate (anti-PRP)

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 g/mL.

    Time frame: At Month 7

  29. Antibody concentrations for anti-polyribosyl ribitol phosphate (anti-PRP)

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 g/mL.

    Time frame: At pre-booster vaccination (Month 0 BST)

  30. Antibody concentrations for anti-polyribosyl ribitol phosphate (anti-PRP)

    Concentrations were expressed as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 g/mL.

    Time frame: At Month 1 post-booster vaccination

  31. Number of subjects with solicited general symptoms

    The solicited local symptoms assessed were Drowsiness, Temperature (Fever), Irritability and Loss of appetite. Temperature = Fever ≥ 38.0 °C. Grade 3 drowsiness = drowsiness that prevented normal activity; Grade 3 irritability = crying that could not be comforted/prevented normal activity; Grade 3 loss of appetite = not eating at all; Grade 3 Temperature = \> 39.5 °C. Related = symptoms considered by the investigator to have a causal relationship to vaccination.

    Time frame: During the 8-day (Day 0-Day 7) follow-up period after the any dose and booster vaccination

  32. Number of subjects with unsolicited adverse events (AES)

    An AE was defined as any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Occurring within Day 0-30 following primary and booster vaccination

07

Study locations

1 site
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
08

References and documents

Publications

  • Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, Siegrist CA, Zepp F. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008 May;152(5):655-60, 660.e1. doi: 10.1016/j.jpeds.2007.09.034. Epub 2007 Nov 19. PubMed 18410769 ↗
  • Knuf M, Schmitt HJ, Jacquet JM, Collard A, Kieninger D, Meyer CU, Siegrist CA, Zepp F. Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr. 2010 Apr;156(4):675-8. doi: 10.1016/j.jpeds.2009.12.019. PubMed 20303444 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Apr 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2006
First posted
Feb 10, 2006
Start
Jul 2004
Primary completionActual
Apr 2006
CompletionActual
Dec 2006
Last update
Feb 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00289796
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 10, 2006
Start date
Jul 2004
Primary completion
Apr 2006
Completion
Dec 2006
Last update
Feb 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion